TCRX
Income statement / Annual
Last year (2024), TScan Therapeutics, Inc.'s total revenue was $2.82 M,
a decrease of 86.62% from the previous year.
In 2024, TScan Therapeutics, Inc.'s net income was -$127.50 M.
See TScan Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$2.82 M |
$21.05 M |
$13.54 M |
$10.14 M |
$1.09 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$88.15 M
|
$5.14 M
|
$3.33 M
|
$20.58 M
|
$519,000.00
|
| Gross Profit |
$2.82 M
|
-$67.10 M
|
$8.40 M
|
$6.81 M
|
-$19.49 M
|
-$519,000.00
|
| Gross Profit Ratio |
1
|
-3.19
|
0.62
|
0.67
|
-17.96
|
0
|
| Research and Development Expenses |
$107.35 M
|
$88.15 M
|
$59.82 M
|
$44.95 M
|
$20.58 M
|
$9.44 M
|
| General & Administrative Expenses |
$30.29 M
|
$26.35 M
|
$20.35 M
|
$13.83 M
|
$6.74 M
|
$4.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$30.29 M
|
$26.35 M
|
$20.35 M
|
$13.83 M
|
$6.74 M
|
$4.77 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.59 M
|
$16,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$137.64 M
|
$114.51 M
|
$80.17 M
|
$58.78 M
|
$27.32 M
|
$14.21 M
|
| Cost And Expenses |
$137.64 M
|
$114.51 M
|
$80.17 M
|
$58.78 M
|
$27.32 M
|
$14.21 M
|
| Interest Income |
$12.07 M
|
$8.00 M
|
$1.59 M
|
$16,000.00
|
$106,000.00
|
$552,000.00
|
| Interest Expense |
$3.65 M
|
$3.76 M
|
$1.18 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.11 M
|
$5.36 M
|
$5.14 M
|
$3.33 M
|
$1.23 M
|
$519,000.00
|
| EBITDA |
-$119.74 M |
-$80.10 M |
-$59.91 M |
-$45.30 M |
-$25.00 M |
-$13.69 M |
| EBITDA Ratio |
-42.52
|
-3.81
|
-4.81
|
-4.47
|
-23.04
|
0
|
| Operating Income Ratio |
-47.88
|
-4.44
|
-4.92
|
-4.8
|
-24.18
|
0
|
| Total Other Income/Expenses Net |
$7.32 M
|
$4.24 M
|
$415,000.00
|
$16,000.00
|
$106,000.00
|
$552,000.00
|
| Income Before Tax |
-$127.50 M
|
-$89.22 M
|
-$66.22 M
|
-$48.63 M
|
-$26.13 M
|
-$13.66 M
|
| Income Before Tax Ratio |
-45.28
|
-4.24
|
-4.89
|
-4.79
|
-24.08
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$415,000.00
|
$3.09 M
|
-$106,000.00
|
-$552,000.00
|
| Net Income |
-$127.50 M
|
-$89.22 M
|
-$65.81 M
|
-$48.63 M
|
-$26.02 M
|
-$13.11 M
|
| Net Income Ratio |
-45.28
|
-4.24
|
-4.86
|
-4.79
|
-23.98
|
0
|
| EPS |
-1.14 |
-1.36 |
-2.74 |
-2.03 |
-1.04 |
-0.53 |
| EPS Diluted |
-1.14 |
-1.36 |
-2.74 |
-2.03 |
-1.04 |
-0.53 |
| Weighted Average Shares Out |
$111.99 M
|
$65.60 M
|
$24.05 M
|
$23.91 M
|
$24.94 M
|
$24.94 M
|
| Weighted Average Shares Out Diluted |
$111.99 M
|
$65.60 M
|
$24.05 M
|
$23.91 M
|
$24.94 M
|
$24.94 M
|
| Link |
|
|
|
|
|
|
